Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025
Pathologic Response to Neoadjuvant Cetuximab, Platinum, and Taxane in Locally Advanced HNSCC.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Raab Gabriel, Xu Bin, Alabkaa Anas, Katabi Nora, Dogan Snjezana, Dunn Lara, Patel Snehal, Sherman Eric J, Pfister David, Tam Kenric, Caxeiro Giovanna, Ghossein Ronald, Cracchiolo Jennifer, Ho Alan L, Ganly Ian, Wong Winston
Аннотация
OBJECTIVE: Taxane, platinum, and cetuximab (TPC) is effective as neoadjuvant therapy for advanced head and neck squamous cell carcinoma (HNSCC) and induces pathologic responses that influences clinical outcomes.
STUDY DESIGN: Retrospective cohort study conducted from 1990 to 2023.
SETTING: Memorial Sloan Kettering Cancer Center.
METHODS: Patients with HNSCC who received TPC/TPF before definitive therapy were retrospectively reviewed. Patients were assessed for radiographic and pathologic response, disease-free survival (DFS), and overall survival (OS). Radiographic response was defined as any tumor shrinkage assessed by a radiologist. Pathologic response on the primary (tumor) and lymph nodes was categorized as complete (pCR), near complete (pNCR), partial (pPR), and no response (pNR), corresponding to treatment effects of 100%, 90%-99%, 11%-89%, and <10%, respectively. Pathologic objective response rate (pORR) = pCR + pNCR + pPR.
RESULTS: Fifty-six patients received TPC; pORR was 71% for the primary tumor and 61% overall (primary + lymph nodes), while the pCR + pNCR rate for primary tumors was 29% and 20% for overall. Radiographic response before definitive surgical treatment was 88%. pORR in the primary tumor was associated with improved DFS (P = .001) and OS (P = .040). Overall pORR showed improved DFS (P = .024) and trend towards improved OS compared to pNR (P = .145).
CONCLUSION: TPC appears to be effective for HNSCC before surgery, and pathologic responses may inform clinical outcomes. Pathologic response criteria defined in this study can establish a standardized and uniform approach for assessment after neoadjuvant treatment for HNSCC.
STUDY DESIGN: Retrospective cohort study conducted from 1990 to 2023.
SETTING: Memorial Sloan Kettering Cancer Center.
METHODS: Patients with HNSCC who received TPC/TPF before definitive therapy were retrospectively reviewed. Patients were assessed for radiographic and pathologic response, disease-free survival (DFS), and overall survival (OS). Radiographic response was defined as any tumor shrinkage assessed by a radiologist. Pathologic response on the primary (tumor) and lymph nodes was categorized as complete (pCR), near complete (pNCR), partial (pPR), and no response (pNR), corresponding to treatment effects of 100%, 90%-99%, 11%-89%, and <10%, respectively. Pathologic objective response rate (pORR) = pCR + pNCR + pPR.
RESULTS: Fifty-six patients received TPC; pORR was 71% for the primary tumor and 61% overall (primary + lymph nodes), while the pCR + pNCR rate for primary tumors was 29% and 20% for overall. Radiographic response before definitive surgical treatment was 88%. pORR in the primary tumor was associated with improved DFS (P = .001) and OS (P = .040). Overall pORR showed improved DFS (P = .024) and trend towards improved OS compared to pNR (P = .145).
CONCLUSION: TPC appears to be effective for HNSCC before surgery, and pathologic responses may inform clinical outcomes. Pathologic response criteria defined in this study can establish a standardized and uniform approach for assessment after neoadjuvant treatment for HNSCC.